Pegylated Liposomal Doxorubicin (Doxil) and Drug Combinations in Multiple Myeloma
June 10th 2010
Current treatment approaches for mutiple myeloma focus on improving progression-free and overall survival. Although five-year survival rates have increased significantly over the past ten years, the prognosis of the disease is generally poor. The availability of several promising new therapies offers clinicians treatment options to further improve response rates, especially through the development of new combination regimens.